Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1083 Vaccine in Adults 50 to <65 Years
NCT06508320Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Jul 2024
- Primary completion
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of mCOMBRIAX in influenza, coronavirus disease 2019 (COVID-19), sponsored by Moderna Inc. Started Jul 2024; status: completed.
02
Drugs
mCOMBRIAX
03
Conditions
influenzacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06508320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06508320.